Campbell & CO Investment Adviser LLC Buys New Shares in Alphatec Holdings, Inc. $ATEC

Campbell & CO Investment Adviser LLC bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 46,709 shares of the medical technology company’s stock, valued at approximately $679,000.

Other large investors have also recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. bought a new position in shares of Alphatec in the 2nd quarter valued at about $37,000. Nisa Investment Advisors LLC lifted its stake in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares during the last quarter. R Squared Ltd bought a new position in Alphatec during the second quarter worth about $114,000. State of Alaska Department of Revenue acquired a new position in Alphatec during the third quarter worth approximately $120,000. Finally, State of Wyoming acquired a new position in Alphatec during the second quarter worth approximately $124,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alphatec in a research note on Monday, December 29th. Barclays raised their price target on Alphatec from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Wednesday, January 7th. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Stifel Nicolaus started coverage on shares of Alphatec in a research report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Alphatec in a report on Monday, January 12th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $22.82.

Alphatec Stock Down 3.3%

ATEC opened at $17.15 on Wednesday. The stock has a fifty day moving average of $20.37 and a 200-day moving average of $16.72. The company has a market capitalization of $2.55 billion, a P/E ratio of -16.49 and a beta of 1.01. Alphatec Holdings, Inc. has a fifty-two week low of $8.81 and a fifty-two week high of $23.29. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. During the same quarter last year, the company posted ($0.28) earnings per share. The company’s revenue was up 30.4% on a year-over-year basis. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insiders Place Their Bets

In related news, COO Scott Lish sold 19,900 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $19.64, for a total transaction of $390,836.00. Following the sale, the chief operating officer owned 641,432 shares of the company’s stock, valued at $12,597,724.48. This represents a 3.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David M. Demski sold 30,000 shares of Alphatec stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $21.20, for a total value of $636,000.00. Following the completion of the transaction, the director directly owned 399,623 shares of the company’s stock, valued at $8,472,007.60. This represents a 6.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,403,342 shares of company stock valued at $69,816,381 in the last quarter. Company insiders own 22.80% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.